➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Boehringer Ingelheim
McKesson
Mallinckrodt

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 7,279,565

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,279,565
Title:Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
Abstract: The exposure of cells, tissues and organs to \"stress,\" such as elevated temperature, stimulates production of active heat stress transcription factors (HSF), which in turn, induce expression of genes regulated by stress promoters. Normally, the activity of stress promoters declines after cells, tissues and organs are returned to a normal condition. The present invention relates to molecular circuits that provide for sustained expression of a gene of interest subsequent to a single application of stress. Generally, the molecular circuits of the invention comprise (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter or a combination promoter activatable by stress and by the transcription factor, wherein the first promoter or the combination promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the second promoter and the gene of interest are operably linked.
Inventor(s): Voellmy; Richard (Pully, Vaud, CH)
Assignee:
Application Number:10/996,420
Patent Claims:see list of patent claims

Details for Patent 7,279,565

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial 2018-05-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial 2018-05-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial 2018-05-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Mallinckrodt
Merck
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.